| 1996 | P-glycoprotein as an intermediate end point of drug resistance to neoadjuvant chemotherapy in locally advanced gastric cancer
| YONSEI MEDICAL JOURNAL |
| 1997 | P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2021 | p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer | BIOCHEMICAL PHARMACOLOGY |
| 1998 | p53 유전자 변형이 발생한 위암세포주에서 유전자이상 교정에 의한 항암제 감수성 변화
| Journal of the Korean Cancer Association (대한암학회지) |
| 2010 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2022 | PD-L1 expression and overall survival in Asian and western patients with gastric cancer | FUTURE ONCOLOGY |
| 2020 | Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies | JOURNAL OF THORACIC ONCOLOGY |
| 2019 | Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
| Gastric Cancer |
| 2016 | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial | LANCET ONCOLOGY |
| 2018 | Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
| CANCER SCIENCE |
| 2023 | Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial | LANCET |
| 2018 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial | LANCET |
| 2022 | Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2008 | Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 1995 | Perioperative blood transfusions and prognosis in patients with curatively resected locally advanced gatric cancer | ONCOLOGY |
| 2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
| 2008 | Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer | RADIOTHERAPY AND ONCOLOGY |
| 2014 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2008 | Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
| ANNALS OF ONCOLOGY |
| 2010 | Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer | RADIOTHERAPY AND ONCOLOGY |
| 2011 | Phase II study of sunitinib as second-line treatment for advanced gastric cancer
| INVESTIGATIONAL NEW DRUGS |
| 2019 | Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer | RADIOTHERAPY AND ONCOLOGY |
| 2008 | Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
| ANNALS OF ONCOLOGY |
| 1998 | Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients | BREAST CANCER RESEARCH AND TREATMENT |
| 2015 | PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity | INTERNATIONAL JOURNAL OF CANCER |
| 2009 | Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. | INTERNATIONAL JOURNAL OF ONCOLOGY |
| 2013 | Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer
| BMC CANCER |
| 2009 | Prediction of recurrence of early gastric cancer after curative resection | ANNALS OF SURGICAL ONCOLOGY |
| 2009 | Prediction of S-1-induced anemia | GASTRIC CANCER |
| 2011 | Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer | ANTI-CANCER DRUGS |
| 2011 | Prevalence and associated factors of psychological distress among Korean cancer patients | GENERAL HOSPITAL PSYCHIATRY |
| 2017 | Prevalence and prognostic implications of psychological distress in patients with gastric cancer
| BMC CANCER |
| 1995 | Primary lymphoma of thyroid
| YONSEI MEDICAL JOURNAL |
| 2023 | Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response
| CELL REPORTS MEDICINE |
| 2022 | Probe-Based Confocal Laser Endomicroscopy versus White-Light Endoscopy with Narrow-Band Imaging for Predicting and Collecting Residual Cancer Tissue in Patients with Gastric Cancer Receiving Chemotherapy
| CANCERS |
| 2009 | Prognosis of pN3 stage gastric cancer
| CANCER RESEARCH AND TREATMENT |
| 2007 | Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single Institute | JOURNAL OF SURGICAL ONCOLOGY |
| 2016 | Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma
| BMC CANCER |
| 2018 | Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.
| BMC CANCER |
| 2020 | Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial
| JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE |
| 2021 | Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer
| CANCER MEDICINE |
| 2016 | Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. | ANNALS OF NUCLEAR MEDICINE |
| 2013 | Prognostic Value of Mucinous Histology Depends on Microsatellite Instability Status in Patients with Stage III Colon Cancer Treated with Adjuvant FOLFOX Chemotherapy: A Retrospective Cohort Study | ANNALS OF SURGICAL ONCOLOGY |
| 2015 | Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer | ANNALS OF SURGICAL ONCOLOGY |
| 2015 | PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer | ONCOLOGY |
| 2017 | PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
| ONCOTARGET |
| 2007 | Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents | ONCOLOGY REPORTS |
| 2014 | Quality of Life in the Trastuzumab for Gastric Cancer Trial | ONCOLOGIST |
| 2017 | Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY |
| 2012 | Quantitative analysis of ERK signaling inhibition in colon cancer cell lines using phospho-specific flow cytometry | ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY |
| 2005 | Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients | INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE |
| 2017 | Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study | EUROPEAN JOURNAL OF CANCER |
| 2018 | Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. | JOURNAL OF GLOBAL ONCOLOGY |
| 2015 | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | LANCET ONCOLOGY |
| 2019 | Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer | EUROPEAN JOURNAL OF CANCER |
| 2013 | Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
| SUPPORTIVE CARE IN CANCER |
| 2013 | Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. | NATURE MEDICINE |
| 2018 | Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial | CLINICAL CANCER RESEARCH |
